ATRA can induce MDSCs to differentiate into mature myeloid cells, and combination treatment with an anti-PD-L1 immune checkpoint inhibitor enhanced anti-tumour efficacy against cervical cancer [98]. This evidence concerns the gene CD274 and neoplasm.